Cambridge Investment Research Advisors Inc. boosted its stake in CareDx (NASDAQ:CDNA) by 125.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 64,426 shares of the company’s stock after buying an additional 35,851 shares during the period. Cambridge Investment Research Advisors Inc. owned approximately 0.23% of CareDx worth $473,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in CDNA. Royce & Associates LP grew its stake in CareDx by 8.1% in the 3rd quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after buying an additional 59,500 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of CareDx during the 4th quarter worth approximately $130,000. FNY Partners Fund LP acquired a new position in shares of CareDx during the 4th quarter worth approximately $102,000. Perkins Capital Management Inc. grew its position in shares of CareDx by 28.9% during the 4th quarter. Perkins Capital Management Inc. now owns 178,639 shares of the company’s stock worth $1,311,000 after purchasing an additional 40,089 shares in the last quarter. Finally, Private Wealth Partners LLC grew its position in shares of CareDx by 85.5% during the 4th quarter. Private Wealth Partners LLC now owns 436,000 shares of the company’s stock worth $3,200,000 after purchasing an additional 201,000 shares in the last quarter. Institutional investors and hedge funds own 51.50% of the company’s stock.
Shares of NASDAQ:CDNA opened at $9.02 on Friday. CareDx has a 12-month low of $0.76 and a 12-month high of $9.28. The company has a market cap of $252.66, a price-to-earnings ratio of -11.71 and a beta of 0.37. The company has a current ratio of 0.62, a quick ratio of 0.50 and a debt-to-equity ratio of -3.08.
CDNA has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine lowered shares of CareDx from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of CareDx in a research report on Wednesday, January 31st. Finally, TheStreet upgraded shares of CareDx from a “d-” rating to a “c-” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $8.65.
In related news, insider Peter Maag sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $7.87, for a total transaction of $118,050.00. Following the sale, the insider now owns 272,037 shares in the company, valued at approximately $2,140,931.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.40% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.